Already registered?
Please login.
Program Overview
The pathophysiology of psoriasis is now recognized as dysregulation of activated T cells and overproduction of pro-inflammatory cytokines. Traditional therapies for more severe forms of psoriasis have included systemic immunosuppressive agents such as methotrexate and cyclosporine, which offer acute relief but at the cost of serious side effects. Our understanding of psoriasis immunopathology has led to development of several highly effective biologic agents to treat this disease. However, dermatologists still face many questions regarding biologic therapies for psoriasis - when should patients be switched to biologic therapies? How does one choose a particular biologic agent for a given patient? What are the differences among the agents in terms of safety, efficacy, dosing, and mechanism of action? And how can I translate the latest study findings into my clinical practice?
This program provides healthcare professionals with an opportunity to view new information on the treatment of Psoriasis presented at this year's meeting of the American Academy of Dermatology in San Antonio, Texas. The goal is to examine the potential impact of the new data on clinical practice and patient outcomes. The role of existing and emerging biologic therapies in the treatment of psoriasis will be emphasized.
